Mutation of all runx (AML1/Core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns

Journal of Virology

Volumn 78, Issue 23, 2004, Pages 13216-13231

  Sørensen, Karina Dalsgaard ^a   Quintanilla Martinez, Leticia ^b   Kunder, Sandra ^b   Schmidt, Jörg ^b   Pedersen, Finn Skou ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN;

ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; ENHANCER REGION; ERYTHROID CELL; FLOW CYTOMETRY; GENE DELETION; GENE DUPLICATION; GENE INSERTION; GENOME ANALYSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MATURATION; MORPHOLOGICAL TRAIT; MOUSE; MURINE LEUKEMIA VIRUS; MUTATION; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; SOUTHERN BLOTTING; T CELL LYMPHOMA; T LYMPHOCYTE; VIRUS CARCINOGENESIS; VIRUS MORPHOLOGY;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD11B; ANTIGENS, CD43; BASE SEQUENCE; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE SUSCEPTIBILITY; DNA-BINDING PROTEINS; ENHANCER ELEMENTS (GENETICS); LEUKEMIA VIRUS, MURINE; LEUKEMIA, MYELOID; LYMPHOMA, T-CELL; MICE; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEINS; SIALOGLYCOPROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TRANSCRIPTION FACTORS;

EID: 8644268080     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.23.13216-13231.2004     Document Type: Article

References (78)

1. Bae, S. C., Y. Yamaguchi-Iwai, E. Ogawa, M. Maruyama, M. Inuzuka, H. Kagoshima, K. Shigesada, M. Satake, and Y. Ito. 1993. Isolation of PEBP2 alpha B cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1. Oncogene 8:809-814.
2. Bedigian, H. G., D. A. Johnson, N. A. Jenkins, N. G. Copeland, and R. Evans. 1984. Spontaneous and induced leukemias of myeloid origin in recombinant inbred BXH mice. J. Virol. 51:586-594.
3. Bergeron, D., J. Houde, L. Poliquin, B. Barbeau, and E. Rassart. 1993. Expression and DNA rearrangement of proto-oncogenes in Cas-Br-E-induced non-T-, non-B-cell leukemias. Leukemia 7:954-962.
4. Boral, A. L., S. A. Okenquist, and J. Lenz. 1989. Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element. J. Virol. 63:76-84.
5. Bundy, L. M., M. Ru, B.-F. Zheng, L. Cheng, P. K. Pattengale, J. L. Portis, and H. Fan. 1995. Biological characterization and molecular cloning of murine c-type retrovirus derived from the TSZ complex from mainland China. Virology 212:367-382.
6. Celander, D., and W. A. Haseltine. 1984. Tissue-specific transcription preference as a determinant of cell tropism and leukaemogenic potential of murine retroviruses. Nature 312:159-162.
7. Chatis, P. A., C. A. Holland, J. W. Hartley, W. P. Rowe, and N. Hopkins. 1983. Role for the 3′ end of the genome in determining disease specificity of Friend and Moloney murine leukemia viruses. Proc. Natl. Acad. Sci. USA 80:4408-4411.
8. Chatis, P. A., C. A. Holland, J. E. Silver, T. N. Frederickson, N. Hopkins, and J. W. Hartley. 1984. A 3′ end fragment encompassing the transcriptional enhancers of nondefective Friend virus confers erythroleukemogenicity on Moloney leukemia virus. J. Virol. 52:248-254.
9. Coffman, J. A. 2003. Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol. Int. 27:315-324.
10. DesGroseillers, L., and P. Jolicoeur. 1984. The tandem direct repeats within the long terminal repeat of murine leukemia viruses are the primary determinant of their leukemogenic potential. J. Virol. 52:945-952.
11. Ethelberg, S., B. Hallberg, J. Lovmand, J. Schmidt, A. Luz, T. Grundström, and F. S. Pedersen. 1997. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site. J. Virol. 71:1196-1206.
12. Ethelberg, S., J. Lovmand, J. Schmidt, A. Luz, and F. S. Pedersen. 1997. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 marine leukemia virus by a second-site enhancer variant evolved in vivo. J. Virol. 71:7273-7280.
13. Ethelberg, S., A. B. Sørensen, J. Schmidt, A. Luz, and F. S. Pedersen. 1997. An SL3-3 murine leukemia virus enhancer variant more pathogenic than the wild type obtained by assisted molecular evolution in vivo. J. Virol. 71:9796-9799.
14. Fredrickson, T. N., W. Y. Langdon, P. M. Hoffman, J. W. Hartley, and H. C. Morse III. 1984. Histologic and cell surface antigen studies of hematopoietic tumors induced by Cas-Br-M murine leukemia virus. J. Natl. Cancer Inst. 72:447-454.
15. Goldrath, A. W., and M. J. Bevan. 1999. Selecting and maintaining a diverse T-cell repertoire. Nature 402:255-262.
16. Golemis, E. A., N. A. Speck, and N. Hopkins. 1990. Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design. J. Virol. 64:534-542.
17. Granger, S. W., L. Bundy, and H. Fan. 1999. Tandemerization of a subregion of the enhancer sequences from SRS 19-6 murine leukemia virus associated with T-lymphoid but not other leukemias. J. Virol. 73:7175-7184.
18. Gulley, M. L., L. C. Ogata, J. A. Thorson, M. O. Dailey, and J. D. Kemp. 1988. Identification of a murine pan-T cell antigen which is also expressed during the terminal phases of B cell differentiation. J. Immunol. 140:3751-3757.
19. Hallberg, B., J. Schmidt, A. Luz, F. S. Pedersen, and T. Grundström. 1991. SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus. J. Virol. 65:4177-4181.
20. Hanecak, R., P. K. Pattengale, and H. Fan. 1991. Deletion of a GC-rich region flanking the enhancer element within the long terminal repeat sequences alters the disease specificity of Moloney murine leukemia virus. J. Virol. 65:5357-5363.
21. Hardy, R. R., C. E. Carmack, S. A. Shinton, J. D. Kemp, and K. Hayakawa. 1991. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J. Exp. Med. 173:1213-1225.
22. Hays, E. F., and G. Bristol. 1992. Observations on lymphomagenesis and lymphoma in AKR mice. A description of prelymphoma changes in the thymus and phenotypic diversity of lymphomas induced by SL3-3 virus. Thymus 19:219-234.
23. Hays, E. F., G. C. Bristol, S. McDougall, J. L. Klotz, and M. Kronenberg. 1989. Development of lymphoma in the thymus of AKR mice treated with the lymphomagenic virus SL 3-3. Cancer Res. 49:4225-4230.
24. Jaffe, E. S., N. L. Harris, H. Stein, and J. W. Vardiman (ed.). 2001. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. IARC Press, Lyon, France.
25. Jones, A. T., B. Federsppiel, L. G. Ellies, M. J. Williams, R. Burgener, V. Duronio, C. A. Smith, F. Takei, and H. J. Ziltener. 1994. Characterization of the activation-associated isoform of CD43 on murine T lymphocytes. J. Immunol. 153:3426-3439.
26. Kogan, S. C., J. M. Ward, M. R. Anver, J. J. Berman, C. Brayton, R. D. Cardiff, J. S. Carter, S. de Coronado, J. R. Downing, T. N. Fredrickson, D. C. Haines, A. W. Harris, N. L. Harris, H. Hiai, E. S. Jaffe, I. C. MacLennan, P. P. Pandolfi, P. K. Pattengale, A. S. Perkins, R. M. Simpson, M. S. Tuttle, J. F. Wong, and H. C. Morse III. 2002. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100:238-245.
27. Lagasse, E., and I. L. Weissman. 1996, Flow cytometric identification of murine neutrophils and monocytes. J. Immunol. Methods 197:139-150.
28. Largaespada, D. A. 2000. Genetic heterogeneity in acute myeloid leukemia: maximizing information flow from MuLV mutagenesis studies. Leukemia 14:1174-1184.
29. Lazo, P. A., A. J. Klein-Szanto, and P. N. Tsichlis. 1990. T-cell lymphoma lines derived from rat thymomas induced by Moloney murine leukemia virus: phenotypic diversity and its implications. J. Virol. 64:3948-3959.
30. Leib-Mösch, C., J. Schmidt, M. Etzerodt, F. S. Pedersen, R. Hehlmann, and V. Erfle. 1986. Oncogenic retrovirus from spontaneous murine osteomas. II. Molecular cloning and genomic characterization. Virology 150:96-105.
31. Lenz, J., D. Celander, R. L. Crowther, R. Patarca, D. W. Perkins, and W. A. Haseltine. 1984. Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature 308:467-470.
32. Lenz, J., R. Crowther, S. Klimenko, and W. Haseltine. 1982. Molecular cloning of a highly leukemogenic, ecotropic retrovirus from an AKR mouse. J. Virol. 43:943-951.
33. Levanon, D., V. Negreanu, Y. Bernstein, I. Bar-Am, L. Avivi, and Y. Groner. 1994. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics 23:425-432.
34. Lewis, A. F., T. Stacy, W. R. Green, L. Taddesse-Heath, J. W. Hartley, and N. A. Speck. 1999. Core-binding factor influences the disease specificity of Moloney murine leukemia virus. J. Virol. 73:5535-5547.
35. Liu, P., S. A. Tarle, A. Hajra, D. F. Claxton, P. Marlton, M. Freedman, M. J. Siciliano, and F. S. Collins. 1993. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 261:1041-1044.
36. LoSardo, J. E., A. L. Boral, and J. Lenz. 1990. Relative importance of elements within the SL3-3 virus enhancer for T-cell specificity. J. Virol. 64: 1756-1763.
37. Lovmand, J., A. B. Sørensen, J. Schmidt, M. Østergaard, A. Luz, and F. S. Pedersen. 1998. B-Cell lymphoma induction by Akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer. J. Virol. 72:5745-5756.
38. Lund, A. H., J. Schmidt, A. Luz, A. B. Sørensen, M. Duch, and F. S. Pedersen. 1999. Replication and pathogenidty of primer binding site mutants of SL3-3 murine leukemia viruses. J. Virol. 73:6117-6122.
39. Lund, A. H., and M. van Lohuizen. 2002. RUNX: a trilogy of cancer genes. Cancer Cell 1:213-215.
40. Manley, N. R., M. O'Connell, W. Sun, N. A. Speck, and N. Hopkins. 1993. Two factors that bind to highly conserved sequences in mammalian type C retroviral enhancers. J. Virol. 67:1967-1975.
41. Martiney, M. J., L. S. Levy, and J. Lenz. 1999. Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus. J. Virol. 73:2143-2152.
42. Martiney, M. J., K. Ruli, R. Beaty, L. S. Levy, and J. Lenz. 1999. Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus. J. Virol. 73:7599-7606.
43. Melnikova, I. N., B. E. Crute, S. Wang, and N. A. Speck. 1993. Sequence specificity of the core-binding factor. J. Virol. 67:2408-2411.
44. Miyoshi, H., K. Shimizu, T. Kozu, N. Maseki, Y. Kaneko, and M. Ohki. 1991. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA 88:10431-10434.
45. Moore, T., M. Bennett, and V. Kumar. 1995. Transplantable NK cell progenitors in murine bone marrow. J. Immunol. 154:1653-1663.
46. Moore, T., S. Huang, L. W. Terstappen, M. Bennett, and V. Kumar. 1994. Expression of CD43 on murine and human pluripotent hematopoietic stem cells. J. Immunol. 153:4978-4987.
47. Morrison, H. L., B. Soni, and J. Lenz. 1995. Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus. J. Virol. 69:446-455.
48. Morse, H. C., III, M. R. Anver, T. N. Fredrickson, D. C. Haines, A. W. Harris, N. L. Harris, E. S. Jaffe, S. C. Kogan, I. C. MacLennan, P. K. Pattengale, and J. M. Ward. 2002. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 100:246-258.
49. Mucenski, M. L., B. A. Taylor, N. A. Jenkins, and N. G. Copeland. 1986. AKXD recombinant inbred strains: models for studying the molecular genetic basis of murine lymphomas. Mol. Cell. Biol. 6:4236-4243.
50. Nieves, A., L. S. Levy, and J. Lenz. 1997. Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3. J. Virol. 71:1213-1219.
51. Ogawa, E., M. Inuzuka, M. Maruyama, M. Satake, M. Naito-Fujimoto, Y. Ito, and K. Shigesada. 1993. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. Virology 194:314-331.
52. Ogawa, E., M. Maruyama, H. Kagoshima, M. Inuzuka, J. Lu, M. Satake, K. Shigesada, and Y. Ito. 1993. PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc. Natl. Acad. Sci. USA 90:6859-6863.
53. Okuda, T., J. van Deursen, S. W. Hiebert, G. Grosveld, and J. R. Downing. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330.
54. Ott, D. E., J. Keller, K. Sill, and A. Rein. 1992. Phenotypes of murine leukemia virus-induced tumors: influence of 3′ viral coding sequences. J. Virol. 66:6107-6116.
55. Rassart, E., J. Houde, C. Denicourt, M. Ru, C. Barat, E. Edouard, L. Poliqnin, and D. Bergeron. 1996. Molecular analysis and characterization of two myeloid leukemia inducing murine retroviruses. Curr. Top. Microbiol. Immunol. 211:201-210.
56. Relink, A. G., E. ten Boekel, T. Yamagami, R. Ceredig, J. Andersson, and F. Melchers. 1999. B cell development in the mouse from early progenitors to mature B cells. Immunol. Lett. 68:89-93.
57. Ru, M., C. Shustik, and E. Rassart. 1993. Graffi murine leukemia virus: molecular cloning and characterization of the myeloid leukemia-inducing agent. J. Virol. 67:4722-4731.
58. Sanderson, R. D., P. Lalor, and M. Bernfield. 1989. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1:27-35.
59. Schmidt, J., V. Erfle, F. S. Pedersen, H. Rohmer, H. Schetters, K. H. Marquart, and A. Luz. 1984. Oncogenic retrovirus from spontaneous murine osteomas. I. Isolation and biological characterization. J. Gen. Virol. 65: 2237-2248.
60. Schmidt, J., A. Luz, and V, Erfle. 1988. Endogenous murine leukemia viruses: frequency of radiation-activation and novel pathogenic effects of viral isolates. Leuk. Res. 12:393-403.
61. Speck, N. A., B. Renjifo, E. Golemis, T. N. Fredrickson, J. W. Hartley, and N. Hopkins. 1990. Mutation of the core or adjacent LVb elements of the Moloney murine leukemia virus enhancer alters disease specificity. Genes Dev. 4:233-242.
62. Speck, N. A., T. Stacy, Q. Wang, T. North, T. L. Gu, J. Miller, M. Binder, and M. Marin-Padilla. 1999. Core-binding factor: a central player in hematopoiesis and leukemia. Cancer Res. S9:1789s-1793s.
63. Sun, W., M. O'Connell, and N. A. Speck. 1993. Characterization of a protein that binds multiple sequences in mammalian type C retrovirus enhancers. J. Virol. 67:1976-1986.
64. Taniuchi, I., M. Osato, T. Egawa, M. J. Sunshine, S. C. Bae, T. Komori, Y. Ito, and D. R. Littman. 2002. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 111:621-633.
65. Thornell, A., B. Hallberg, and T. Grundström. 1991. Binding of SL3-3 enhancer factor 1 transcriptional activators to viral and chromosomal enhancer sequences. J. Virol. 65:42-50.
66. Thornell, A., B. Hallberg, and T. Grundström. 1988. Differential protein binding in lymphocytes to a sequence in the enhancer of the mouse retrovirus SL3-3. Mol. Cell. Biol. 8:1625-1637.
67. Vaillant, F., K. Blyth, L. Andrew, J. C. Neil, and E. R. Cameron. 2002. Enforced expression of Runx2 perturbs T cell development at a stage coincident with beta-selection. J. Immunol. 169:2866-2874.
68. Voura, E. B., F. Billia, N. N. Iscove, and R. G. Hawley. 1997. Expression mapping of adhesion receptor genes during differentiation of individual hematopoietic precursors. Exp. Hematol. 25:1172-1179.
69. Wang, Q., T. Stacy, J. D. Miller, A. F. Lewis, T. L. Gu, X. Huang, J. H. Bushweller, J. C. Bories, F. W. Alt, G. Ryan, P. P. Liu, A. Wynshaw-Boris, M. Binder, M. Marin-Padilla, A. H. Sharpe, and N. A. Speck. 1996. The CBF-beta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 87: 697-708.
70. Wang, S., Q. Wang, B. E. Crute, I. N. Melnikova, S. R. Keller, and N. A. Speck. 1993. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol. Cell. Biol. 13: 3324-3339.
71. Wang, S. W., and N. A. Speck. 1992. Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers. Mol. Cell. Biol. 12:89-102.
72. Wells, S. M., A. B. Kantor, and A. M. Stall. 1994. CD43 (S7) expression identifies peripheral B cell subsets. J. Immunol. 153:5503-5515.
73. Wolff, L. 1997. Contribution of oncogenes and tumor suppressor genes to myeloid leukemia. Biochim. Biophys. Acta 1332:F67-F104.
74. Wolff, L., R. Koller, X. Hu, and M. R. Anver. 2003. A Moloney murine leukemia virus-based retrovirus with 4070A long terminal repeat sequences induces a high incidence of myeloid as well as lymphoid neoplasms. J. Virol. 77:4965-4971.
75. Woolt, E., C. Xiao, O. Fainaru, J. Lotem, D. Rosen, V. Negreanu, Y. Bernstein, D. Goldenberg, O. Brenner, G. Berke, D. Levanon, and Y. Groner. 2003. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc. Natl. Acad. Sci. USA 100:7731-7736.
76. Zaiman, A. L., and J. Lenz. 1996. Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb. J. Virol. 70:5618-5629.
77. Zaiman, A. L., A. F. Lewis, B. E. Crute, N. A. Speck, and J. Lenz. 1995. Transcriptional activity of core binding factor-alpha (AML1) and beta sub-units on murine leukemia virus enhancer cores. J. Virol. 69:2898-2906.
78. Zaiman, A. L., A. Nieves, and J. Lenz. 1998. CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes. J. Virol. 72:3129-3137.